Related Experiment Video
Updated: Jul 10, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
No relation between angiotensin-converting enzyme gene polymorphism and pseudoexfoliation.
Oya Tekeli1, M Erol Turaçli, Buket Altinok
1Department of Ophthalmology, Faculty of Medicine, Ankara University, Ankara, Turkey. oyatekeli@tr.net
Ophthalmic Research
|November 21, 2007
Summary
The angiotensin-converting enzyme insertion/deletion (I/D) polymorphism is not associated with pseudoexfoliation (PEX) in Turkish patients. This genetic variation does not appear to contribute to the development of PEX disease.
Area of Science:
- Ophthalmology
- Genetics
- Internal Medicine
Background:
- Pseudoexfoliation (PEX) is an ocular disorder associated with increased risk of glaucoma.
- The angiotensin-converting enzyme (ACE) gene I/D polymorphism has been investigated in various diseases.
Purpose of the Study:
- To investigate the association between the ACE gene I/D polymorphism and PEX in a Turkish population.
- To determine if ACE I/D polymorphism is a risk factor for PEX development.
Main Methods:
- Prospective case-control study involving 89 PEX patients and 120 controls.
- Genotyping of the ACE I/D polymorphism was performed using polymerase chain reaction (PCR).
Main Results:
- No significant difference in the distribution of ACE I/D polymorphism between PEX patients and controls.
- Allele frequencies (I and D) of the ACE gene were comparable between the two groups.
Conclusions:
- The ACE gene I/D polymorphism does not appear to play a role in the pathogenesis of pseudoexfoliation.
- Findings suggest that this specific genetic variation is not a risk factor for PEX in the studied Turkish cohort.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:09Epistasis Analysis
Although Mendel chose seven unrelated traits in peas to study gene segregation, most traits involve multiple gene interactions that create a spectrum of phenotypes. When the interaction of various genes or alleles at different locations influences a phenotype, this is called epistasis. Epistasis often involves one gene masking or interfering with the expression of another (antagonistic epistasis). Epistasis often occurs when different genes are part of the same biochemical pathway. The...
02:32Exon Recombination
The evolution of new genes is critical for speciation. Exon recombination, also known as exon shuffling or domain shuffling, is an important means of new gene formation. It is observed across vertebrates, invertebrates, and in some plants such as potatoes and sunflowers. During exon recombination, exons from the same or different genes recombine and produce new exon-intron combinations, which might evolve into new genes.
Exon shuffling follows “splice frame rules.” Each exon has three reading...
Exon shuffling follows “splice frame rules.” Each exon has three reading...